Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status
Authors
Keywords
Multiple Sclerosis, Experimental Autoimmune Encephalomyelitis, Hepatocyte Growth Factor, Natalizumab, Fingolimod
Journal
Molecular Diagnosis & Therapy
Volume 18, Issue 6, Pages 605-617
Publisher
Springer Nature
Online
2014-08-27
DOI
10.1007/s40291-014-0117-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis
- (2014) Tessel F Runia et al. Multiple Sclerosis Journal
- Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
- (2014) J. Romme Christensen et al. NEUROLOGY
- Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis
- (2013) Roopali Gandhi et al. ANNALS OF NEUROLOGY
- Current methods for the isolation of extracellular vesicles
- (2013) Fatemeh Momen-Heravi et al. BIOLOGICAL CHEMISTRY
- The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis
- (2013) Pietro Iaffaldano et al. BRAIN BEHAVIOR AND IMMUNITY
- MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
- (2013) Michael Hecker et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA
- (2013) Marleen J.A. Koel-Simmelink et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis
- (2013) Lenka Fialová et al. JOURNAL OF NEUROIMMUNOLOGY
- Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica
- (2013) Yuko Shimizu et al. JOURNAL OF NEUROIMMUNOLOGY
- The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis
- (2013) Markus Axelsson et al. JOURNAL OF NEUROIMMUNOLOGY
- Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients
- (2013) Marcel P. Stoop et al. JOURNAL OF PROTEOME RESEARCH
- Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity
- (2013) Levente Szalardy et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- MicroRNAs in the Brain: It's Regulatory Role in Neuroinflammation
- (2013) Menaka C. Thounaojam et al. MOLECULAR NEUROBIOLOGY
- Cell-cell communication via extracellular membrane vesicles and its role in the immune response
- (2013) Inkyu Hwang MOLECULES AND CELLS
- Differential microRNA expression in blood in multiple sclerosis
- (2013) Helle Bach Søndergaard et al. Multiple Sclerosis Journal
- CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions
- (2013) Enrique Alvarez et al. Multiple Sclerosis Journal
- Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development
- (2013) Pia Kivisäkk et al. Multiple Sclerosis Journal
- Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season
- (2013) Grant P Parnell et al. Multiple Sclerosis Journal
- Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis
- (2013) Violaine K Harris et al. Multiple Sclerosis Journal
- Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
- (2013) Charlotte Teunissen et al. Multiple Sclerosis Journal
- Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis
- (2013) Chiara Fenoglio et al. Multiple Sclerosis Journal
- Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
- (2013) Markus Axelsson et al. Multiple Sclerosis Journal
- Gene expression analysis of relapsing–remitting, primary progressive and secondary progressive multiple sclerosis
- (2013) R Ratzer et al. Multiple Sclerosis Journal
- Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
- (2013) Marta F. Bustamante et al. PLoS One
- Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis
- (2013) Signe Modvig et al. PLoS One
- Extracellular vesicles as mediators of neuron-glia communication
- (2013) Carsten Frühbeis et al. Frontiers in Cellular Neuroscience
- Roles of exosomes and microvesicles in disease pathogenesis
- (2012) Shin-ichiro Ohno et al. ADVANCED DRUG DELIVERY REVIEWS
- Myeloid microvesicles are a marker and therapeutic target for neuroinflammation
- (2012) Claudia Verderio et al. ANNALS OF NEUROLOGY
- Altered microRNA expression in B lymphocytes in multiple sclerosis
- (2012) Claudia Sievers et al. CLINICAL IMMUNOLOGY
- The genetics of multiple sclerosis: an up-to-date review
- (2012) Pierre-Antoine Gourraud et al. IMMUNOLOGICAL REVIEWS
- Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
- (2012) Afsaneh Shirani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis
- (2012) Andre Michael Müller et al. JOURNAL OF NEUROIMMUNOLOGY
- Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients
- (2012) Shi-Rong Wen et al. JOURNAL OF NEUROIMMUNOLOGY
- CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
- (2012) Markus C Kowarik et al. Journal of Neuroinflammation
- Exacerbation of Experimental Autoimmune Encephalomyelitis in the Absence of Breast Regression Protein 39/Chitinase 3-Like 1
- (2012) Dafna Bonneh-Barkay et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Circulating microRNAs involved in multiple sclerosis
- (2012) Sue Rutherford Siegel et al. MOLECULAR BIOLOGY REPORTS
- Disease Biomarkers in Multiple Sclerosis
- (2012) Violaine K. Harris et al. Molecular Diagnosis & Therapy
- Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13
- (2012) M Lindén et al. Multiple Sclerosis Journal
- Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression
- (2012) CE Teunissen et al. Multiple Sclerosis Journal
- Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis
- (2012) Arie R Gafson et al. Multiple Sclerosis Journal
- CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis
- (2012) Jeppe Romme Christensen et al. Multiple Sclerosis Journal
- CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
- (2012) M Khalil et al. Multiple Sclerosis Journal
- Neurofilaments as biomarkers in multiple sclerosis
- (2012) Charlotte E Teunissen et al. Multiple Sclerosis Journal
- Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
- (2012) Anke Vennegoor et al. Multiple Sclerosis Journal
- Progressive multiple sclerosis: pathology and pathogenesis
- (2012) Hans Lassmann et al. Nature Reviews Neurology
- Antigen microarrays identify CNS-produced autoantibodies in RRMS
- (2012) F. J. Quintana et al. NEUROLOGY
- Serum IL-17F does not predict poor response to IM IFN -1a in relapsing-remitting MS
- (2012) S. E. Bushnell et al. NEUROLOGY
- Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study
- (2012) A. Haghikia et al. NEUROLOGY
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab combination therapy in relapsing multiple sclerosis
- (2012) Anne H. Cross et al. Therapeutic Advances in Neurological Disorders
- Implication of the toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis
- (2011) Marta F. Bustamante et al. ANNALS OF NEUROLOGY
- The neurofilament light chain is not stable in vitro
- (2011) Marleen J.A. Koel-Simmelink et al. ANNALS OF NEUROLOGY
- Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury
- (2011) Chun Geun Lee et al. Annual Review of Physiology
- Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid
- (2011) A. S.T. Lourenco et al. CURRENT MOLECULAR MEDICINE
- Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis
- (2011) Kathryn M. Brennan et al. JOURNAL OF NEUROIMMUNOLOGY
- Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing–remitting multiple sclerosis
- (2011) Natascha Helena Beyer et al. JOURNAL OF NEUROIMMUNOLOGY
- CD49d expression as a promising biomarker to monitor natalizumab efficacy
- (2011) Gilles Defer et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
- (2011) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid
- (2011) Samia Ragheb et al. Multiple Sclerosis Journal
- The Level of Isoprostanes as a Non-invasive Marker for in vivo Lipid Peroxidation in Secondary Progressive Multiple Sclerosis
- (2011) Elżbieta Miller et al. NEUROCHEMICAL RESEARCH
- Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
- (2011) J. Kuhle et al. NEUROLOGY
- Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple Sclerosis
- (2011) Richard A. Rudick et al. PLoS One
- Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
- (2011) Anne Waschbisch et al. PLoS One
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
- (2010) Martin Gunnarsson et al. ANNALS OF NEUROLOGY
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
- (2010) Laura Piccio et al. ARCHIVES OF NEUROLOGY
- Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
- (2010) Manuel Comabella et al. BRAIN
- A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein
- (2010) Jens Kuhle et al. JOURNAL OF NEUROIMMUNOLOGY
- Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers
- (2010) Jan Ottervald et al. Journal of Proteomics
- Neurofilament light as a prognostic marker in multiple sclerosis
- (2010) Jonatan Salzer et al. Multiple Sclerosis Journal
- Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the ‘Spinal Tap’
- (2010) Gavin Giovannoni Multiple Sclerosis Journal
- Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
- (2010) Begoña Oliver et al. Multiple Sclerosis Journal
- Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis
- (2010) Lars Börnsen et al. Multiple Sclerosis Journal
- Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
- (2010) Mohsen Khademi et al. Multiple Sclerosis Journal
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis
- (2010) Robert C Axtell et al. NATURE MEDICINE
- Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis
- (2010) Violaine K. Harris et al. NEUROBIOLOGY OF DISEASE
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
- (2010) Johannes Brettschneider et al. PLoS One
- Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells
- (2009) Michael Gurevich et al. BMC Medical Genomics
- A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis
- (2009) M. Comabella et al. BRAIN
- The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
- (2009) M. Khademi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
- (2009) F. Sellebjerg et al. NEUROLOGY
- Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
- (2009) C. E. Teunissen et al. NEUROLOGY
- A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
- (2009) C. E. Teunissen et al. NEUROLOGY
- CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis
- (2009) H. Tumani et al. NEUROSCIENCE LETTERS
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Specificity and Correlation With Disease Activity of Cerebrospinal Fluid Osteopontin Levels in Patients With Multiple Sclerosis
- (2008) Soheli A. Chowdhury et al. ARCHIVES OF NEUROLOGY
- Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission
- (2008) Ariel T Arthur et al. BMC Medical Genetics
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
- (2008) Lisa G. M. van Baarsen et al. PLoS One
- Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event
- (2008) J.-C. Corvol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
- (2008) F. J. Quintana et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started